{
    "clinical_study": {
        "@rank": "52023", 
        "arm_group": [
            {
                "arm_group_label": "adductor canal block with tibial nerve block", 
                "arm_group_type": "Active Comparator", 
                "description": "Continuous adductor canal block and single shot posterior tibial nerve block (bolus: 0.5% Ropivacaine 20ml ; infusion of 0.2% Ropivacaine at 6ml/h) with single shot posterior tibial nerve block (8-10ml 0.5% ropivacaine)"
            }, 
            {
                "arm_group_label": "periarticular infiltration", 
                "arm_group_type": "Other", 
                "description": "periarticular infiltration with ropivacaine, ketorolac and epinenephrine (total 50ml 0.2% ropivacaine with 20mg ketorolac and epinephrine 5mcg/ml for anterior and posterior structures infiltrations; 25ml 0.2% ropivacaine with ketorolac 10mg for subcutaneous infiltration) ."
            }
        ], 
        "brief_summary": {
            "textblock": "We hypothesize continuous adductor canal block with single shot tibial nerve block would\n      offer better anaglesics with rehabilitation ability for postoperative patients receiving\n      total knee arthroplasty."
        }, 
        "brief_title": "Randomized Controlled Trial of Total Knee Replacement Postoperative Analgesia Using Combined Continuous Adductor Canal Block and Single Shot Tibial Nerve Block vs Periarticular Infiltration in Chinese Population", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Focus on Analgesic Efficacy and Rehabilitation Profile of Patients Receiving Two Types of Pain Interventions for Postop Pain After Total Knee Arthroplasty", 
        "condition_browse": {
            "mesh_term": "Pain, Postoperative"
        }, 
        "detailed_description": {
            "textblock": "Method:\n\n      A total of 60 patients who will undergo total knee arthroplasty will be randomized into two\n      groups:\n\n      Treatment groups Treatment details Group A Continuous adductor canal block and single shot\n      posterior tibial nerve block (bolus: 0.5% Ropivacaine 20ml ; infusion of 0.2% Ropivacaine at\n      6ml/h) with single shot posterior tibial nerve block (8-10ml 0.5% ropivacaine) Group B\n      periarticular infiltration with ropivacaine, ketorolac and epinenephrine (total 50ml 0.2%\n      ropivacaine with 20mg ketorolac and epinephrine 5mcg/ml for anterior and posterior\n      structures infiltrations; 25ml 0.2% ropivacaine with ketorolac 10mg for subcutaneous\n      infiltration) .\n\n      Two groups will receive the same preemptive and postoperative multimodal regime for\n      perioperative analgesia. All groups will receive standardized method of spinal anaesthesia\n      for surgery."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u2022 Diagnosis of primary osteoarthritis\n\n               -  Scheduled for elective total knee arthroplasty\n\n               -  Signed written informed consent\n\n               -  Planned use of spinal anaesthesia\n\n               -  Cognitive sound to use assessment tools\n\n        Exclusion Criteria:\n\n          -  \u2022 Patients refusing to give consents\n\n               -  Cognitive impairment/ inability to use the outcome assessment tools\n\n               -  Contraindications to regional anesthesia\n\n               -  severe cardiovascular disease (unstable angina, second or third degree heart\n                  block)\n\n               -  pre-existing neurologic disease including psychiatric disorder\n\n               -  drug abuser\n\n               -  Pre-operative history of neurological abnormality in the ipsilateral leg e.g.\n                  history of stroke, neurogenic pain or previous nerve injury.\n\n               -  Allergy or contraindication to drugs used in this study: morphine, NSAID\n                  (ketorolac , diclofenac), dihydrocodeine, local anaesthetics (lignoacaine,\n                  ropicavaine, bupivacaine), epinenephrine\n\n               -  Moderate or severe renal impairment (serum creatinine > 160 micromol/l)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01973530", 
            "org_study_id": "BHJRC_HK_TKR_Study_2014"
        }, 
        "intervention": [
            {
                "arm_group_label": "adductor canal block with tibial nerve block", 
                "intervention_name": "adductor canal block and tibial nerve block", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "periarticular infiltration", 
                "intervention_name": "periarticular infiltration", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 30, 2013", 
        "number_of_arms": "2", 
        "official_title": "Project Title: Randomized Controlled Trial of Total Knee Replacement Postoperative Analgesia Using Combined Continuous Adductor Canal Block and Single Shot Tibial Nerve Block vs Periarticular Infiltration in Chinese Population", 
        "overall_contact": {
            "email": "huikmg@ha.org.hk", 
            "last_name": "Grace Hui, MBBS FHKAM FHKCA", 
            "phone": "29586202"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Hong Kong: Ethics Committee"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "PCA morphine or pain rescuer consumption at 24h and 48h postop", 
            "safety_issue": "No", 
            "time_frame": "24h and 48h postop"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01973530"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Queen Elizabeth Hospital, Hong Kong", 
            "investigator_full_name": "Dr Hui Kit Man Grace", 
            "investigator_title": "Associate Consultant, Dept of Anaesthesia and Operating Services", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Postop pain score (visual analogue scale 0-10) at 6h,12h, 24h,48h, 72h after surgery", 
                "safety_issue": "No", 
                "time_frame": "6h, 12h, 24h, 48h postop"
            }, 
            {
                "measure": "Active range of motion at 24h, 48h, 72h postop", 
                "safety_issue": "No", 
                "time_frame": "24h, 48h, 72h postop"
            }, 
            {
                "measure": "Quadriceps strength of operated leg at 24h, 48h, 72h postop", 
                "safety_issue": "No", 
                "time_frame": "24h, 48h, 72h postop"
            }, 
            {
                "measure": "Patient satisfaction score (0-4)", 
                "safety_issue": "No", 
                "time_frame": "upon discharge"
            }, 
            {
                "measure": "Incidence of side effects and complications at postop day 0- 96h  postop", 
                "safety_issue": "Yes", 
                "time_frame": "postoperative period 0-96 hr postop"
            }, 
            {
                "measure": "Length of Stay in hospital  6. Length of Stay in hospital length of hospital stay", 
                "safety_issue": "No", 
                "time_frame": "upon discharge"
            }
        ], 
        "source": "Queen Elizabeth Hospital, Hong Kong", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Queen Elizabeth Hospital, Hong Kong", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}